NCT00714246View on ClinicalTrials.gov

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Bortezomib

Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

DRUG

Carboplatin

Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

DRUG

Docetaxel

Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Trial Locations (1)

17033

Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Milton S. Hershey Medical Center

OTHER